Combination of sorafenib and capsaicin exhibited an enhanced antitumor activity in hepatocellular carcinoma and renal cell carcinoma in mice
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-071-Tuesday
- By: GAO, Jianjun (Qingdao, China)
- Co-author(s): Jianjun Gao: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Yuhao Ni: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Sushan Zhang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Chenru Zhao: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Zhen Qiao: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Hongxia Yu: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Luyao Wang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Jinyan Sun: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Chen Du: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Jiahao Zhang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Liying Dong: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
Ke-Wei Wang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China - Abstract:
Backgrounds
Sorafenib, a small inhibitor of tyrosine protein kinases, is currently used as a first-line drug to treat advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Capsaicin displays antitumor activity alone and enhances the sensitivity of cancer cells to cytotoxic drugs.Aims
The present study aims to investigate the.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023